Josép María
Ribera Santasusana
Publikationen, an denen er mitarbeitet Josép María Ribera Santasusana (15)
2020
-
Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols
European Journal of Haematology, Vol. 105, Núm. 2, pp. 138-147
2011
-
Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens
Blood, Vol. 117, Núm. 6, pp. 1799-1805
-
Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance
Blood, Vol. 118, Núm. 17, pp. 4547-4553
2010
-
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomised trial
The Lancet Oncology, Vol. 11, Núm. 10, pp. 934-941
-
Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial
Haematologica, Vol. 95, Núm. 1, pp. 87-95
2008
-
Prognostic value of immunophenotyping in multiple myeloma: A study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy
Journal of Clinical Oncology, Vol. 26, Núm. 16, pp. 2737-2744
2007
-
CTLA-4 polymorphisms and clinical outcome after allogeneic stem cell transplantation from HLA-identical sibling donors
Blood, Vol. 110, Núm. 1, pp. 461-467
2005
-
Minimal residual disease monitoring in multiple myeloma: A comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry
Haematologica, Vol. 90, Núm. 10, pp. 1365-1372
2001
-
Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracycline-based protocol. A report from the spanish group PETHEMA
Haematologica, Vol. 86, Núm. 8, pp. 807-813
-
Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate-risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIAL
Haematologica, Vol. 86, Núm. 6, pp. 586-595
-
Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RARα isoforms: A study of the PETHEMA group
British Journal of Haematology, Vol. 114, Núm. 1, pp. 99-103
2000
-
Definition of relapse risk and role of nonanthracycline drags for consolidation in patients with acute promyelocytic leukemia: A joint study of the PETHEMA and GIMEMA cooperative groups
Blood, Vol. 96, Núm. 4, pp. 1247-1253
-
Detection of inv(16) and t(16;16) by fluorescence in situ hybridization in acute myeloid leukemia M4Eo
Haematologica, Vol. 85, Núm. 5, pp. 481-485
1999
1998
-
Peripheral T-cell lymphomas: Initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification
Annals of Oncology, Vol. 9, Núm. 8, pp. 849-855